BR100 Increased By (0.01%)
BR30 Decreased By (-1.15%)
KSE100 Increased By (0.09%)
KSE30 Decreased By (-0.05%)
AGHA 6.02 Decreased By ▼ -0.03 (-0.5%)
BECO 3.81 Decreased By ▼ -0.02 (-0.52%)
BML 56.44 Decreased By ▼ -1.89 (-3.24%)
BOP 28.10 Decreased By ▼ -0.25 (-0.88%)
CNERGY 12.28 Decreased By ▼ -1.36 (-9.97%)
CSIL 5.29 Increased By ▲ 0.08 (1.54%)
FCCL 53.81 Increased By ▲ 1.53 (2.93%)
FFL 12.80 Decreased By ▼ -0.10 (-0.78%)
FNEL 1.12 Decreased By ▼ -0.01 (-0.88%)
KEL 5.64 Decreased By ▼ -0.15 (-2.59%)
KOSM 5.38 Decreased By ▼ -0.13 (-2.36%)
LOTCHEM 23.55 Decreased By ▼ -0.34 (-1.42%)
MLCF 91.96 Increased By ▲ 1.45 (1.6%)
NBP 162.24 Increased By ▲ 2.52 (1.58%)
NCPL 48.91 Decreased By ▼ -0.69 (-1.39%)
NPL 50.51 Decreased By ▼ -1.29 (-2.49%)
OGDC 301.68 Decreased By ▼ -5.10 (-1.66%)
PACE 9.13 Decreased By ▼ -0.02 (-0.22%)
PAEL 31.81 Decreased By ▼ -0.52 (-1.61%)
PIBTL 12.78 Decreased By ▼ -0.15 (-1.16%)
PPL 212.06 Decreased By ▼ -1.87 (-0.87%)
PRL 87.26 Decreased By ▼ -9.70 (-10%)
PTC 43.96 Decreased By ▼ -1.23 (-2.72%)
SSGC 22.86 Increased By ▲ 0.33 (1.46%)
TBL 8.91 Decreased By ▼ -0.11 (-1.22%)
TELE 6.44 Decreased By ▼ -0.28 (-4.17%)
TPL 24.09 Decreased By ▼ -1.82 (-7.02%)
TPLP 12.16 Decreased By ▼ -0.44 (-3.49%)
TREET 23.50 Increased By ▲ 0.04 (0.17%)
TRG 51.87 Decreased By ▼ -0.09 (-0.17%)
World

Swedes under 65 to be given alternative to AstraZeneca vaccine for second dose

  • Sweden paused the use of the AstraZeneca vaccine in March after reports of rare but serious blood clots among people vaccinated with the AstraZeneca shot. Sweden later resumed use but only for people aged 65 or above.
Published Updated
By

STOCKHOLM: Swedes under 65 vaccinated with one shot of the AstraZeneca COVID-19 vaccine will be given a different vaccine for the second dose, the Swedish Health Agency said on Tuesday.

Sweden paused the use of the AstraZeneca vaccine in March after reports of rare but serious blood clots among people vaccinated with the AstraZeneca shot. Sweden later resumed use but only for people aged 65 or above.

"People under the age of 65 who have already received a dose of Vaxzevria should instead be offered a second dose of so-called mRNA vaccine, such as PfizerBiontech or Moderna," the Health Agency said in a statement.

Comments

Comments are closed for this article.